Cis-dichlorodiammineplatinum upregulates angiotensin II type 1 receptors through reactive oxygen species generation and enhances VEGF production in bladder cancer

Molecular Cancer Therapeutics

Volumn 9, Issue 11, 2010, Pages 2982-2992

  Tanaka, Nobuyuki ^a   Miyajima, Akira ^a   Kosaka, Takeo ^a   Shirotake, Suguru ^a   Hasegawa, Masanori ^a   Kikuchi, Eiji ^a   Oya, Mototsugu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CISPLATIN; OLMESARTAN; REACTIVE OXYGEN METABOLITE; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTECTOMY; DRUG POTENTIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; CISPLATIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 1; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78649643021     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0535     Document Type: Article

References (34)

1. See S, String AL. Candesartan cilexetil: an angiotensin II-receptor blocker. Am J Health Syst Pharm 2000;57:739-46. (Pubitemid 30220015)
2. Fujimoto Y, Sasaki T, Tsuchida A, et al. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett 2001;495:197-200. (Pubitemid 32397704)
3. Egami K, Murohara T, Shimada T, et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 2003;112:67-75.
4. Koh WP, Yuan JM, Van Den Berg D, et al. Polymorphisms in angiotensin II type 1 receptor and angiotensin 1-converting enzyme genes and breast cancer risk among Chinese women in Singapore. Carcinogenesis 2005;26:459-64. (Pubitemid 40246568)
5. Jullerat JL, Celerier J, Chapuis BC, et al. Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. Br J Cancer 2004;90:1059-68.
6. Fujita M, Hayashi I, Yamashina S, et al. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 2002;294:441-7. (Pubitemid 34694114)
7. Lever AF, Hole DJ, Gills CR, et al. Do inhibitors of angiotensin-1- converting enzyme protect against risk of cancer? Lancet 1998;352:179-84.
8. Miyajima A, Kosaka T, Asano T, et al. Angiotensin II type 1 antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 2002;62:4176-9.
9. Kosugi M, Miyajima A, Kikuchi E, et al. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res 2006;12:2888-93. (Pubitemid 43752131)
10. Kosaka T, Miyajima A, Takayama E, et al. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 2007;67:41-9.
11. Kosugi M, Miyajima A, Kikuchi E, et al. Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer. Hum Cell 2007;20:1-9. (Pubitemid 46761472)
12. Kosugi M, Miyajima A, Kikuchi E, et al. Angiotensin II type 1 receptor antagonist enhances cis-dichlorodiammineplatinum-induced cytotoxicity in mouse xenograft model of bladder cancer. Urology 2009;73:655-60.
13. Jamieson ER, Lippard SJ. Structure, recognition and processing of cisplatin-DNA adducts. Chem Rev 1999;99:2467-98.
14. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79.
15. Miyajima A, Nakashima J, Yoshioka K, et al. Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cells. Br J Cancer 1997;76:206-10. (Pubitemid 27279660)
16. Miyajima A, Nakashima J, Tachibana M, et al. N-acetylcysteine modifies cis-dichlorodiammineplatinum-induced effects in bladder cancer cells. Jpn J Cancer Res 1999;90:565-70. (Pubitemid 29267711)
17. Nickenig G, Roling J, Strehlow K, et al. Insulin induces up-regulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation 1998;98:2453-60. (Pubitemid 28549791)
18. Xu ZG, Yuan H, Lanting L, et al. Products of 12/15-lipoxygenase up-regulate the angiotensin II receptor. J Am Soc Nephrol 2008;19:559-69.
19. Gragasin FS, Xu Y, Arenas IA, et al. Estrogen reduces angiotensin II-induced nitric oxide synthase and NAD(P)H oxidase expression in endothelial cells. Arterioscler Thromb Vasc Biol 2003;23:38-44. (Pubitemid 36091623)
20. Linthout SV, Spillmann F, Lorenz M, et al. Vascular-protective effects of high-density lipoprotein include the downregulation of the angiotensin II type 1 receptor. Hypertension 2009;53:682-7.
21. Pelicano H, Carney D, Huang P, et al. ROS stress in cancer cells and therapeutic implications. Drug Resist Update 2004:97-110. (Pubitemid 38736063)
22. Tachibana M. Studies on cellular adhesiveness in five different culture cell lines derived from carcinoma of the urinary bladder. Keio J Med 1982;31:127-48. (Pubitemid 13065842)
23. Tachibana M, Miyakawa A, Nakashima J, et al. Constitutive production of multiple cytokines and a human chorionic gonadotropin β-subunit by a human bladder cancer cell line (KU-19-19): possible demonstration of totipotential differentiation. Br J Cancer 1997;76:163-74.
24. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003;361:1927-34.
25. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;48:859-66.
26. Kosaka T, Miyajima A, Shirotake S, et al. Est-1 and hypoxia inducible factor-1α inhibition by angiotensin II type 1 receptor blockade in hormone-refractory prostate cancer. Prostate 2009;70:162-9.
27. Wilop S, Hobe SV, Crysandt M, et al. Impact of angiotensin 1 converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol 2009:135:1429-35.
28. Watanabe T, Yuki S, Egawa M, et al. Prevention effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro. Prostaglandins Leukot Essent Fatty Acids 1988;33:81-7.
29. Kawai H, Nakai H, Suga M, et al. Effects of a novel free radical scavenger, MCI-186, on ischemic brain damage in the rat distal middle cerebral artery occlusionmodel. J Pharmacol Exp Ther 1997;281:921-7. (Pubitemid 27203828)
30. Yamamoto T, Yuki S, Watanabe T, et al. Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia. Brain Res 1997;762:240-2.
31. Lev DC, Onn A, Melinkova VO, et al. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol 2004;22:2092-100.
32. Lev DC, Ruiz M, Mills L, et al. Dacarbazine causes transcriptional upregulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther 2003;2:753-63.
33. Levina V, Su Y, Nolen B, et al. Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer 2008;123:2031-40.
34. Inoue K, Slaton JW, Karashima T, et al. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 2000;6:4866-73.